ORGANIC
LETTERS
Total Synthesis of (±
)-Galanthamine‡
2006
Vol. 8, No. 9
1823-1825
Xiang-Dong Hu, Yong Qiang Tu,* En Zhang, Shuanhu Gao, Shaohua Wang,
Aixia Wang, Chun-An Fan, and Min Wang
State Key Laboratory of Applied Organic Chemistry and Department of Chemistry,
Lanzhou UniVersity, Lanzhou 730000, PRC
Received February 8, 2006
ABSTRACT
A practical and efficient total synthesis of (
which the construction of its core structure and the special allylic alcohol group were based on a successive semipinacol rearrangement/
desilyation/cyclization and Saegusa Ito oxidation, respectively.
±)-galanthamine was achieved from commercially available materials through a novel approach, in
−
Galanthamine (1),1 the parent member of the galanthamine-
type Amaryllidaceae alkaloids, is a centrally acting competi-
tive and reversible inhibitor of acetylcholinesterase (Ache),
which significantly enhances cognitive functions of patients
suffering from Alzheimer’s disease and was first approved
in Austria and most recently in the rest of Europe and in the
United States for the treatment of Alzheimer’s disease.2 To
date, several elegant total syntheses of 1 were developed,3
in which the key transformations involved the construction
of two units: (i) the universal tricyclic benzofuran core A
with a sterically congested quaternary carbon, which was
shared by galanthamine-type and morphine-type alkaloids
(Figure 1), and (ii) the special C3 allylic alcohol moiety,
which is essential for its anticholinesterase activity.4 In
constructing the universal skeleton, many synthetic strategies,
such as biomimetic phenolic oxidative coupling,3a-n photo-
chemical reaction,5 radical cyclization,6 intramolecular Heck
reaction,3o-r semipinacol rearrangement,7 intermolecular
alkylation,8 and arylation,9 had been utilized. However, the
successful introduction of the allylic alcohol moiety only
relied on two protocols, biomimetic oxidative bisphenol
(3) (a) Barton, D. H. R.; Kirby, G. W. J. Chem. Soc. 1962, 806. (b)
Kametani, T.; Yamaki, K.; Yagi, H.; Fukumoto, K. J. Chem. Soc. D 1969,
425. (c) Kametani, T.; Yamaki, K.; Yagi, H.; Fukumoto, K. J. Chem. Soc.
C 1969, 2602. (d) Kametani, T.; Yamaki, K.; Terui, T. J. Heterocycl. Chem.
1973, 10, 35. (e) Shimizu, K.; Tomioka, K.; Yamada, S.; Koga, K.
Heterocycles 1977, 8, 277. (f) Shimizu, K.; omioka, K.; Yamada, S.; Koga,
K. Chem. Pharm. Bull. 1978, 26, 3765. (g) Krikorian, D.; Vlahov, R.;
Parushev, S.; Chinova, M.; Vlahov, I.; Schaefer, H. J.; Duddeck, H.; Snatzke,
G. Tetrahedron Lett. 1984, 25, 2969. (h) Vlahov, R.; Krikorian, D.; Spassov,
G.; Chinova, M.; Vlahov, I.; Parushev, S.; Snatzke, G.; Ernst, L.; Kieslich,
K.; Abraham, W. R.; Sheldrick, W. S. Tetrahedron 1989, 45, 3329. (i)
Szewczyk, J.; Wilson, J. W.; Lewin, A. H.; Carroll, F. I. J. Heterocycl.
Chem. 1995, 32, 195. (j) Chaplin, D. A.; Fraser, N.; Tiffin, P. D. Tetrahedron
Lett. 1997, 38, 7931. (k) Czollner, L.; Frantsits, W.; Kenburg, B.; Hedenig,
U.; Frohlich, J.; Jordis, U. Tetrahedron Lett. 1998, 39, 2087. (l) Kita, Y.;
Arisawa, M.; Gyoten, M.; Nakajima, M.; Hamada, R.; Tohma, H.; Takada,
T. J. Org. Chem. 1998, 63, 6625. (m) Krikorian, D.; Tarpanov, V.; Parushev,
S.; Mechkarova, P. Synth. Commun. 2000, 30, 2833. (n) Node, M.; Kodama,
S.; Hamashima, Y.; Baba, T.; Hamamichi, N.; Nishide, K. Angew. Chem.,
Int. Ed. 2001, 40, 3060. (o) Trost, B. M.; Toste, F. D. J. Am. Chem. Soc.
2000, 122, 11262. (p) Guillou, C.; Beunard, J.-L.; Gras, E.; Thal, C. Angew.
Chem., Int. Ed. 2001, 40, 4745. (q) Trost, B. M.; Tang, W. Angew. Chem.,
Int. Ed. 2002, 41, 2795. (r) Parsons, J. P.; Charles, M. D.; Harvey, D. M.;
Sumoreeah, L. R.; Shell, A.; Spoors, G.; Gill, A. L.; Smith, S. Tetrahedron
Lett. 2001, 42, 2209.
‡ The new approach to galanthamine is under application for the Chinese
Patent (No. 200610041682.6).
(1) For reviews, see: (a) Hoshino, O. In The Alkaloids; Cordell, G. A.,
Ed.; Academic Press: New York, 1998; Vol. 51, pp 323-424. (b) Martin,
S. F. In The Alkaloids; Brossi, A., Ed.; Academic Press: New York, 1987;
Vol. 30, pp 251-376. (c) Marco-Contelles, J.; Carreiras, M. D. C.;
Rodriguez, C.; Villarroya, M.; Garcia, A. G. Chem. ReV. 2006, 106, 116.
(2) (a) Rainer, M. Drugs Today 1997, 33, 273. (b) Mucke, H. A. M.
Drugs Today 1997, 33, 251. (c) Gaicobini, E. Neurochem. Int. 1998, 32,
413. (d) Weinstock, M. CNS Drugs 1999, 12, 307. (e) Unni, K. CNS Drugs
1998, 10, 447. (f) Nordberg, A.; Svensson, A. L. Drug Safety 1998, 19, 45.
(4) (a) Mary, A.; Renko, Z. D.; Guillou, C.; Thal, C. Bioorg. Med. Chem.
1998, 6, 1835. (b) Guillou, C.; Mary, A.; Renko, Z. D.; Gras, E.; Thal, C.
Bioorg. Med. Chem. Lett. 2000, 10, 637. (c) Greenblatt, H. M.; Guillou,
C.; Guenard, D.; Argaman, A.; Botti, S.; Badet, B.; Thal, C.; Silman, I.;
Sussman, J. L. J. Am. Chem. Soc. 2004, 126, 15405.
10.1021/ol060339b CCC: $33.50
© 2006 American Chemical Society
Published on Web 03/31/2006